BLDR vs KTOS

The company exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet fundamentals. However, despite this strength, the business is facing significant near-term headwinds, evidenced by sharp year-over-year declines in revenue (-6.9%) and earnings (-54.9%), which are weighing on performance. Valuation metrics suggest the stock is trading at a premium to both Graham’s defensive value ($67.26) and growth-based intrinsic value ($36.05), though below the sector’s elevated average P/E. Analysts maintain a 'buy' recommendation with a $131.00 target, implying upside potential if macro or operational conditions improve.

KTOS exhibits severe fundamental divergence, highlighted by a weak Piotroski F-Score of 2/9 and a massive valuation gap where the current price ($70.34) dwarfs the Graham Number ($5.88) and Intrinsic Value ($3.83). While the company shows strong top-line revenue growth (21.9%) and a consistent track record of earnings beats, its current P/E of 541.08 is unsustainable. The combination of bearish insider selling, a 0/100 technical trend, and razor-thin profit margins (1.63%) suggests the stock is priced for perfection in a high-risk environment.